BioTech Social Media and Updates

Black‑Box Warnings Can Slash Drug Revenues—Investors Beware
SocialApr 3, 2026

Black‑Box Warnings Can Slash Drug Revenues—Investors Beware

Approved drugs can have a "black box" (aka boxed) warning, the highest safety-related warning that FDA can put on an approved drug Usually applied to multiple drugs in the same class it can hamper revenue potential if alternatives exist Investors should be...

By Biotech Investor
Annotate Second Methionine when CDS Begins with MM
SocialApr 3, 2026

Annotate Second Methionine when CDS Begins with MM

Question: If a transcript has a CDS that starts with two methionines, what's the general rule for sequence annotation? Should I make it so if two METs in a row at the beginning, annotate the closest MET to rest of sequence...

By Sebastian Cocioba
Japan Approves Conditional Stem‑cell Parkinson’s Replacement Therapy
SocialApr 3, 2026

Japan Approves Conditional Stem‑cell Parkinson’s Replacement Therapy

Woah. I'm slightly embarrassed that I missed this for a few weeks. Finally there is approval, in a Large Nation, for a stem cell-based REPLACEMENT therapy for an age-related condition. The condition is, no surprise, Parkinson's, which I always highlight...

By Aubrey de Grey
Personalized NAD Boosting Needed; Redox Fingerprints Reveal Disease
SocialApr 3, 2026

Personalized NAD Boosting Needed; Redox Fingerprints Reveal Disease

Dynamics of blood NAD and glutathione in health, disease, aging and under NAD-booster treatment “In healthy population (n=299;18-70 year-olds) redox metabolites follow normal distribution in blood and remain unchanged during aging. NAD-boosting increased 4-6 fold the blood NAD+ depending on individual,...

By David Barzilai, MD PhD
Mono Infection Triples Risk of Developing Multiple Sclerosis
SocialApr 3, 2026

Mono Infection Triples Risk of Developing Multiple Sclerosis

New study has strengthened link between infectious mono and Multiple Sclerosis. By analyzing 2 decades of health records, researchers found people who contracted mono as teenagers or adults were 3x more likely to develop MS later vs those who didn’t https://t.co/6DLZMEWyU6

By Scott Gottlieb
Cell‑Free DNA Production Ends Decades‑Old Cloning Bottleneck
SocialApr 3, 2026

Cell‑Free DNA Production Ends Decades‑Old Cloning Bottleneck

Most of synthetic biology has been completely transformed in the last decade. DNA manufacturing? Still running on cloning workflows from the 1970s. That's the bottleneck Jodi Barrientos, CEO of @ribbonbiolabs, is tackling head-on — and she's on the @SynBioBeta Main Stage on...

By John Cumbers
H5N1 Bird‑to‑Cattle Spillover Traced Across US
SocialApr 3, 2026

H5N1 Bird‑to‑Cattle Spillover Traced Across US

So pleased to contribute to this preprint on H5N1 spillover from birds to dairy cattle from the Moo Flu Crew, led by the excellent @jepekar. We traced both B3.13 in Texas and D1.1 in Nevada and Arizona to look at...

By Angela Rasmussen
Anthropic Pays $400M for AI Biotech, Touts 38,500% IRR
SocialApr 3, 2026

Anthropic Pays $400M for AI Biotech, Touts 38,500% IRR

Anthropic acquired an AI for biological research startup for just over $400 million. You can read the letter Dimension wrote to their LPs which boasts a 38,513% IRR https://t.co/wneesuT5u7

By Eric Newcomer
Nanosecond Electric Pulses Rejuvenate Aging Endothelial Cells
SocialApr 2, 2026

Nanosecond Electric Pulses Rejuvenate Aging Endothelial Cells

Nanosecond pulsed electric field applications rejuvenate aging endothelial cells by rescuing mitochondrial-to-nuclear retrograde communication https://t.co/DT8GXNLlxO

By Michael Lustgarten, PhD
FDA's Future: New CBER Chief & Rare Disease Flexibility
SocialApr 2, 2026

FDA's Future: New CBER Chief & Rare Disease Flexibility

On this week’s pod, we chatted with @docrodwong about the FDA, the next CBER chief and regulatory flexibility for rare diseases https://t.co/f6L7gwcNsr via @statnews

By Adam Feuerstein
Ancient Ig-Like Domain Controls Disease-Linked SWI/SNF Complexes
SocialApr 2, 2026

Ancient Ig-Like Domain Controls Disease-Linked SWI/SNF Complexes

a (presumably primordial) Ig-like domain regulates the disease relevant SWI/SNF chromatin remodeling complexes that's pretty cool https://t.co/Iit0Swrx0I

By Paul D. Rennert
Blocking KDM4 Reactivates Tumor Suppressor, Halts AML
SocialApr 2, 2026

Blocking KDM4 Reactivates Tumor Suppressor, Halts AML

Scientists have restored a silenced tumor-suppressor gene in mice with acute myeloid leukemia by blocking KDM4 enzymes, suggesting a potential new therapeutic approach that avoids harming normal blood cells. leukemia

By Phys.org Threads
Seeking Alternative Tools for Genetic Code Sequence Search
SocialApr 2, 2026

Seeking Alternative Tools for Genetic Code Sequence Search

Anyone know of software or a web server that can search a sequence for alternative genetic codes? Been trying to install Codetta https://t.co/Wd7IMD23Cy but can't get it running so looking for alternatives.

By Jonathan Eisen
Lowering Barriers Unlocks Biotech’s Biggest Potential
SocialApr 2, 2026

Lowering Barriers Unlocks Biotech’s Biggest Potential

What if the biggest unlock in biotech is simply access? Douglas Crawford built MBC BioLabs to lower barriers and enable 500+ startups. Excited to have him at SynBioBeta 2026. Visit the @SynBioBeta website to read the full article. https://t.co/HEfhvmwZ8i

By John Cumbers
Collaboration Between Bioinformaticians and Wet Biologists Drives Science
SocialApr 2, 2026

Collaboration Between Bioinformaticians and Wet Biologists Drives Science

🧵The most underrated superpower in science: Bioinformaticians and wet biologists working together. Here’s why it matters. https://t.co/PRuGiq6CbV

By Ming Tang
BeamTx's Risto‑cel Shows Promising Phase
SocialApr 2, 2026

BeamTx's Risto‑cel Shows Promising Phase

1/@BeamTx announced the publication of clinical data from its Phase 1/2 BEACON clinical trial evaluating risto-cel - formerly known as $BEAM-101 for the treatment of sickle cell disease (SCD). The data was presented at #ASH25 🧵👇 & was published in...

By Yair Einhorn
Patients Maintain Weight Loss After Discontinuing GLP‑1s, Epic Shows
SocialApr 2, 2026

Patients Maintain Weight Loss After Discontinuing GLP‑1s, Epic Shows

Interesting data from Epic medical records - suggests that for many patients in the "real world", they are able to keep the weight off after stopping GLP1s... https://t.co/dHfYdG6rEX #EpicResearch

By Bruce Booth
Creatine Plus Probiotic Eases Depression via Gut‑brain Energy Boost
SocialApr 2, 2026

Creatine Plus Probiotic Eases Depression via Gut‑brain Energy Boost

1/2) New placebo-controlled human randomized controlled trial finds creatine + a specific probiotic is effective in treating depression. The mechanism is fascinating, involving the probiotic increasing creatine transporters in the gut, leading to increased brain energy metabolism. If you're passionate about this...

By Nick Norwitz MD PhD
Sinclair Reverses Mouse Infertility, Challenges Menopause Limits
SocialApr 2, 2026

Sinclair Reverses Mouse Infertility, Challenges Menopause Limits

David Sinclair's lab just reversed infertility in mice that had been infertile for 6 months. They took 16-month-old mice, the equivalent of a woman well past menopause, and made them produce offspring again. The belief has always been that mammals run out...

By John Cumbers
Young Plasma Boosts Antioxidant Defense, Preserves Aged Lungs
SocialApr 2, 2026

Young Plasma Boosts Antioxidant Defense, Preserves Aged Lungs

Young plasma transfer enhances antioxidant defense and preserves structural integrity in aged lung tissue https://t.co/v1lR1EyCKv https://t.co/ZYJu1qNsDl

By David Barzilai, MD PhD
Biotech Gains as Pharma Approval Success Diverges
SocialApr 2, 2026

Biotech Gains as Pharma Approval Success Diverges

Pharma has varying levels of success developing drugs. That's a boon for biotech Here are the biopharma companies ranked by likelihood of first approval (LoA%) from 2006-2022 $AMGN, $NVO, #Eisai top the list $GSK, #Astellas, $ABBV are at the bottom #learnbiotechinvesting #BiotechPrometheus

By Biotech Investor
Clinicians Invited to Join Controlled MDMA Study at UCL
SocialApr 2, 2026

Clinicians Invited to Join Controlled MDMA Study at UCL

Clinicians: UCL and Drug Science invite you to contribute to a controlled exploration of MDMA’s psychological effects. Eligible participants will undergo two medically supervised sessions at UCL. This work aims to build a psychoanalytically grounded model of its therapeutic action....

By David Nutt
China’s Clinical Trials Surge, Outpacing US and Europe
SocialApr 2, 2026

China’s Clinical Trials Surge, Outpacing US and Europe

In 2010, China accounted for fewer than 8% of global clinical trials. By 2020, it had surpassed both US & Europe in registered trials. By 2024, China was initiating more than 5,000 clinical trials a year — a more than...

By Linda Yueh
Injectable Satellite Livers May Replace Transplants
SocialApr 2, 2026

Injectable Satellite Livers May Replace Transplants

Injectable “satellite livers” could offer an alternative to liver transplantation by Anne Trafton @MIT Learn more: https://t.co/HZg5qoXutb #HealthTech #ArtificialIntelligence #MachineLearning https://t.co/V4W3VUpDbw

By Ron van Loon
New FDA‑approved Oral Weight‑loss Pill Expands Patient Options
SocialApr 2, 2026

New FDA‑approved Oral Weight‑loss Pill Expands Patient Options

So… hot off the press: a NEW weight loss PILL just got FDA approved. We’ve had oral (non-injectable) GLP-1s before — but this is one of the first specifically for weight management. When it reaches Malaysia, it could significantly increase demand...

By Marissa Dinar, MD
Nasal Dantrolene Nanoparticles Curb Inflammation‑induced Depression, Anxiety
SocialApr 2, 2026

Nasal Dantrolene Nanoparticles Curb Inflammation‑induced Depression, Anxiety

Intranasal dantrolene nanoparticles inhibit lipopolysaccharide-induced depression and anxiety behavior in mice [Context: Dantrolene is a skeletal muscle relaxant used for malignant hyperthermia and chronic spasticity from spinal cord injuries, MS, or stroke. It inhibitings calcium release in muscle cells. Common side...

By David Barzilai, MD PhD
Vibecoding Streamlines Transcriptome to Pfam to NCBI Workflow
SocialApr 2, 2026

Vibecoding Streamlines Transcriptome to Pfam to NCBI Workflow

Amazing how far you can push vibecoding if you know what you need and the general theory behind the tool chains needed to get your result. I can now load a transcriptome dataset, find the pfam associated with that transcript,...

By Sebastian Cocioba
Bioelectric Reprogramming Repairs Birth Defects, Sparks Rejuvenation Hope
SocialApr 2, 2026

Bioelectric Reprogramming Repairs Birth Defects, Sparks Rejuvenation Hope

Fixing Birth Defects With Bioelectrical Reprogramming (Featuring Michael Levin, PhD) Aging and rejuvenation next? https://t.co/CHaRqozCph

By Michael Lustgarten, PhD
NEJM Review Overlooks Inflammation in GLP‑1 Drugs
SocialApr 1, 2026

NEJM Review Overlooks Inflammation in GLP‑1 Drugs

A new review of the GLP-1 receptor drugs @NEJM https://t.co/PK03jApZWB surprisingly, the word inflammation only appears once, in this diagram https://t.co/1PeBakBAQb

By Eric Topol
CBP and FDA Seize 5,000 Peptide Packages, Including GLP‑1 Drugs
SocialApr 1, 2026

CBP and FDA Seize 5,000 Peptide Packages, Including GLP‑1 Drugs

5000 packages of peptides seized by CBP and FDA “The seized materials included several GLP-one medications such as retatrutide, semaglutide, and tirzepatide. Officers also found various other peptides prohibited by the U.S. Food and Drug Administration, including MOTS-C, TB10, semax, and...

By Bijan Salehizedah
Vitamin B3 May Undermine Pancreatic Cancer Chemotherapy
SocialApr 1, 2026

Vitamin B3 May Undermine Pancreatic Cancer Chemotherapy

Title and header via the @cwru press release: New research reveals dangers of ‘anti-aging’ supplements in cancer protection Vitamin B3 could be making chemotherapy less effective in pancreatic cancer patients https://t.co/vIfcvuiS6P Discussion + thoughtful debate welcome👇👨‍⚕️ https://t.co/aHewoWeIle

By David Barzilai, MD PhD
AI-Driven Biology Could Slash Drug Trial Failures Dramatically
SocialApr 1, 2026

AI-Driven Biology Could Slash Drug Trial Failures Dramatically

AI for biology will have bigger near term wins. The ability for AI to learn from experiments and predict human biology will have very broad impacts in predicting targets, clinical trials, and precision medicine. Tackling the biggest challenge in Pharma (80%...

By Vijay Pande
Genome Editing Shows Promise for Sickle Cell, Β‑Thalassemia
SocialApr 1, 2026

Genome Editing Shows Promise for Sickle Cell, Β‑Thalassemia

3 new trial results for genome editing of sickle cell disease and β-thalassemia @NEJM https://t.co/qGGdjgKqP5 (with summary Table below) https://t.co/RdiM3urCKJ https://t.co/W15cPAfMoS https://t.co/F3PHKuktPx https://t.co/t6Z35S8L7h

By Eric Topol
New Early-Stage Cancer Drugs Emerge at AACR26
SocialApr 1, 2026

New Early-Stage Cancer Drugs Emerge at AACR26

A look at some promising early stage drug developments coming down the pike at #AACR26. A few of these concepts were not on the radar a couple of years ago: https://t.co/w6oD4CEckq https://t.co/kfR1AXG41K

By Sally Church
NAD+ Decline Drives Cardiac Aging; NR Restores Rhythm
SocialApr 1, 2026

NAD+ Decline Drives Cardiac Aging; NR Restores Rhythm

NAD+ controls circadian rhythmicity during cardiac aging https://t.co/NNVx94IIC8 Fig. 2: Cardiac NAD+ decreases with aging, with restoration by supplementation with nicotinamide riboside. https://t.co/z4uSqKrYjR

By David Barzilai, MD PhD
IVNS1ABP Mutation Triggers Premature Aging and Neurodegeneration
SocialApr 1, 2026

IVNS1ABP Mutation Triggers Premature Aging and Neurodegeneration

A mutation in the IVNS1ABP gene causes a new disease combining premature aging and severe neurological decline by disrupting cell scaffolding, leading to DNA damage and “zombie-like” senescent cells. https://t.co/xtDrjy72h4

By Liz Parrish
Reprogramming Caps at ~75% Epigenetic Age Reversal
SocialApr 1, 2026

Reprogramming Caps at ~75% Epigenetic Age Reversal

🤣 That’s why we make sure the reprogramming technologies we develop can’t take cells back in epigenetic age more than ~75%

By David Sinclair, PhD
New GLP‑1 Pill Approved: Orfoglipron Offers Easier Dosing
SocialApr 1, 2026

New GLP‑1 Pill Approved: Orfoglipron Offers Easier Dosing

New GLP-1 pill approved Foundayo (orfoglipron). Not as much weight loss as oral wegovy but no issues with food or more liquid around taking it. Same price. Not April fools joke.

By Spencer Nadolsky, DO
Light Therapy Eases Fatigue in Hashimoto’s Patients
SocialApr 1, 2026

Light Therapy Eases Fatigue in Hashimoto’s Patients

The effect of photobiomodulation therapy on fatigue and behavioural status in patients with Hashimoto’s thyroiditis https://t.co/AJx5dvqHyw

By Michael Lustgarten, PhD
Doctors Will Swap Pills for Gene Therapies and Epigenetics
SocialApr 1, 2026

Doctors Will Swap Pills for Gene Therapies and Epigenetics

Longevity 2.0: Your next doctor won't prescribe pills—they'll prescribe gene therapies, epigenetic reprogramming, and personalized longevity protocols. Medicine is shifting from "treat symptoms" to "reverse aging at the cellular level."

By Peter H. Diamandis
Aging Immune System Shapes Allergy and Biologic Response
SocialApr 1, 2026

Aging Immune System Shapes Allergy and Biologic Response

Immunosenescence and Allergy: Molecular and Cellular Links Between Inflammaging, Neuro-Immune Aging, and Response to Biologic Therapies https://t.co/DMVxerI64T https://t.co/TUPGK6SqUK

By David Barzilai, MD PhD
Lilly's Obesity Drug Cleared, Heats up Novo Rivalry
SocialApr 1, 2026

Lilly's Obesity Drug Cleared, Heats up Novo Rivalry

Eli Lilly’s obesity pill approved by FDA, setting up fierce competition with Novo Nordisk https://t.co/8TyrKyyNYP

By Damian Garde
New Transcriptome Browser Streamlines BLAST DB Creation
SocialApr 1, 2026

New Transcriptome Browser Streamlines BLAST DB Creation

Another feature adding to my terminal plasmid editor is a transcriptome browser. Helps you quickly build blast databases from a heap of transcripts in a single fasta file. Gonna add HMM/Pfam detection and Pfam search. I really love this current...

By Sebastian Cocioba
Biotech Platforms Valuation: From mRNA to AI Explained
SocialApr 1, 2026

Biotech Platforms Valuation: From mRNA to AI Explained

Mackenzie published a detailed quantitative analysis of biotech platforms. Good place to start to understand how platform companies from Moderna with mRNA to Isomorphic with AI reach patients and are valued in markets.

By Dan Morehead
FDA Threatens Unprecedented Ban Lift on Untested Injectables
SocialApr 1, 2026

FDA Threatens Unprecedented Ban Lift on Untested Injectables

If FDA does this, which is highly likely succumbing to pressure from RFK Jr, it crosses a new red line and, as far as I know, is unprecedented. Lifting a ban on drugs that are injected into the bloodstream without...

By Eric Topol
ER Binding Sites in MCF7 Cells Span 1,000–20,000
SocialApr 1, 2026

ER Binding Sites in MCF7 Cells Span 1,000–20,000

If I told you the answer to “How many ER binding sites are in MCF7 cells?” is anywhere between 1,000 and 20,000—would you believe me?

By Ming Tang
Biotech's Confidence Game Masks Uncertainty and Risk
SocialApr 1, 2026

Biotech's Confidence Game Masks Uncertainty and Risk

The Confidence Game in Biotech | Ep. 972 https://t.co/RyMgyMVr54 [ 01:12 ] when that trial works [ 01:30 ] manufactured certainty trap [ 02:02 ] linear mental model failure [ 02:33 ] relay race of risk [ 03:31 ] durability risk reality [ 05:29 ] compressing uncertainty...

By BowTiedBiotech
Metformin Undermines Exercise’s Insulin‑Sensitivity Gains
SocialApr 1, 2026

Metformin Undermines Exercise’s Insulin‑Sensitivity Gains

As a medical school professor, I've recommended metformin to countless patients. But a new double-blind trial just revealed something alarming. Metformin BLUNTED the insulin-sensitizing benefits of exercise in adults at risk for metabolic syndrome. The findings from a 16-week RCT: -> Exercise +...

By Robert Lufkin, MD
Advocating Bills to Expand Right‑to‑Try for Severe Illnesses
SocialApr 1, 2026

Advocating Bills to Expand Right‑to‑Try for Severe Illnesses

Today @theA4LI is at the New Hampshire State House supporting HB 1734 and HB 1735, two bills that would license experimental treatment centers and expand Right to Try protections to patients with severe illness, not just terminal conditions. As a longevity...

By David Barzilai, MD PhD